Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers

Iovance Biotherapeutics Inc IOVA has announced data for lifileucel in combination with Merck Co Inc's MRK Keytruda (pembrolizumab) in patients with advanced cancers.
Data were presented at the Society for Immunotherapy of Cancer Annual Meeting.
Early-line treatment with single-agent pembrolizumab achieved an overall response rate (ORR) of 33% in patients with advanced melanoma and 17% in head and neck cancer patients.
Cervical cancer patients previously treated with standard-of-care systemic therapy achieved an ORR of 11%-14% with pembrolizumab monotherapy.
In cervical cancer, melanoma, and head & neck cancer cohorts, ORR was 57.1%, 60%, and 38.9%, respectively.
The treatment-emergent adverse event (TEAE) profile across all three cohorts was consistent with the underlying disease and known adverse event (AE) profiles.
Also Read: Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial.
Price Action: IOVA shares are down 8.23% at $19.34 during the market session on the last check Monday.